NCT04476745

Brief Summary

The effect of Weekly 50,000 IU vitamin D3 supplements on the serum levels of selected cytokines involved in cytokine storm of Covid-19; A randomized clinical trial in the Covid-19 uninfected people with vitamin D deficiency.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2020

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 16, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 20, 2020

Completed
3 months until next milestone

Study Start

First participant enrolled

October 5, 2020

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 22, 2021

Completed
24 days until next milestone

Study Completion

Last participant's last visit for all outcomes

April 15, 2021

Completed
Last Updated

March 9, 2022

Status Verified

February 1, 2022

Enrollment Period

6 months

First QC Date

July 16, 2020

Last Update Submit

February 23, 2022

Conditions

Keywords

Covid -19uninfectedIL-1IL-6TNFVDDVitamin D350,000IU

Outcome Measures

Primary Outcomes (3)

  • IL-1 beta

    seum levels

    8 weeks

  • IL-6

    serum levels

    8 weeks

  • TNF

    serum levels

    8 weeks

Secondary Outcomes (1)

  • serum concentrations of 25-hydroxyvitamin D

    8 weeks

Other Outcomes (1)

  • lipid profile parameters

    8 weeks

Study Arms (2)

Experimental: VD3 group

EXPERIMENTAL

Dietary Supplement: Dietary Supplement: Vitamin D3 Dietary Supplement: Vitamin D3 (50,000) IU / week for 8 weeks Other Names: cholecalciferol,

Dietary Supplement: Vitamin D3

Control group

NO INTERVENTION

Control group No intervention was given

Interventions

Vitamin D3DIETARY_SUPPLEMENT

Dietary Supplement: Vitamin D3 (50,000) IU / week for 8 weeks

Also known as: cholecalciferol
Experimental: VD3 group

Eligibility Criteria

Age30 Years - 66 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥30 years old Male and female Jordanian ASU students and employees who live in Amman. Informed written consent from the participant prior to the start of the study. a serum 25(OH)D concentration less than 30 ng/mL.

You may not qualify if:

  • Any eligible subject refuses to apply with informed written consent before the start of the study. Men or women previously diagnosed with chronic diseases, including kidney disease or GIT problems. Who are receiving vitamin D3 supplements (3 months before the start of the study). Pregnant, Breastfeeding females, Females using hormonal contraceptives

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mahmoud S Abu-Samak

Amman, Jordan

Location

MeSH Terms

Conditions

Cytokine Release SyndromeCOVID-19

Interventions

Cholecalciferol

Condition Hierarchy (Ancestors)

Systemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and SymptomsShockPneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

CholestenesCholestanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSterolsVitamin DSecosteroidsMembrane LipidsLipids

Study Officials

  • Mahmoud S Abu-Samak, PhD

    Department of Clinical Pharmacy and Therapeutics , Applied Science Private University, Amman -Jordan

    STUDY CHAIR
  • Dana A Bader, MSc

    Department of Clinical Pharmacy and Therapeutics , Applied Science Private University, Amman -Jordan

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Mahmoud S Abu-Samak, PhD Study Principal Investigator Department of Clinical Pharmacy and Therapeutics

Study Record Dates

First Submitted

July 16, 2020

First Posted

July 20, 2020

Study Start

October 5, 2020

Primary Completion

March 22, 2021

Study Completion

April 15, 2021

Last Updated

March 9, 2022

Record last verified: 2022-02

Locations